Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

DiagnoCure (PCA3 Prostate Cancer Biomarker Assets)

M&A STATUS
Asset Purch. LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

Molecular testing PROGENSA PCA3 assay diagnostic application. The asset develops diagnostic application for the detection of prostate cancer.

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Acquirer
Primary Office
  • Quebec
  • Canada

DiagnoCure (PCA3 Prostate Cancer Biomarker Assets) Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore DiagnoCure (PCA3 Prostate Cancer Biomarker Assets)‘s full profile, request access.

Request full access to PitchBook

DiagnoCure (PCA3 Prostate Cancer Biomarker Assets) Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore DiagnoCure (PCA3 Prostate Cancer Biomarker Assets)‘s full profile, request access.

Request full access to PitchBook